ATTENTION: SARS-COV-2 | CORONAVIRUS
GenBio Inc. has commenced its SARS-CoV-2 R&D program; its primary focus is to develop and or repurpose a drug(s) with a view to decreasing the severity of secondary infections, particularly pneumonia-causing bacterial pathogens. The company intends to apply for emergency use authorization within six to nine months.
Your US-Based Biotechnology Company.
GenBio, Inc. is a Biotechnology Company specializing in researching a rare natural extract with significant phyto-activity profiles.